NEW YORK, Sept. 12, 2024 /CNW/ – Bright Minds Biosciences Inc. (NASDAQ: DRUG), a biotechnology company focused on developing novel therapies for neurological and neuropsychiatric disorders, today announced the initiation of the BREAKTHROUGH Study, an open-label Phase 2 clinical trial evaluating the safety, tolerability, and efficacy of BMB-101, a highly selective 5-HT2C receptor agonist, in adult patients with…
Fluctuations in blood pressure from midlife to end-of-life: Correlation with dementia risk
Researchers assess the link between year-to-year blood pressure variability at different life stages and the risk of developing dementia.
November 2, 2023